Value of prognostic scores in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis patients in intensive care unit: a multicenter retrospective cohort study from Turkey

UĞUR ÖZDEMİR
NAZMIYE EBRU ORTAÇ ERSOY
RECEP CİVAN YÜKSEL
ERHAN KAYA
ŞAHENDER GÜLBİN AYGENCEL BIKMAZ

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical

Part of the Medical Sciences Commons

Recommended Citation
ÖZDEMİR, UĞUR; ERSOY, NAZMIYE EBRU ORTAÇ; YÜKSEL, RECEP CİVAN; KAYA, ERHAN; BIKMAZ, ŞAHENDER GÜLBİN AYGENCEL; TÜRKOĞLU, MELDA; İSKİT, ARZU TOPELİ; GÜVEN, MUHAMMET; SUNGUR, MURAT; and ALTINTAŞ, NERİMAN DEFINE (2020) "Value of prognostic scores in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis patients in intensive care unit: a multicenter retrospective cohort study from Turkey," Turkish Journal of Medical Sciences: Vol. 50: No. 5, Article 5. https://doi.org/10.3906/sag-1911-86
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss5/5

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.
Value of prognostic scores in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis patients in intensive care unit: a multicenter retrospective cohort study from Turkey

Authors
UĞUR ÖZDEMİR, NAZMİYE EBRU ORTAÇ EROSY, RECEP CİVAN YÜKSEL, ERHAN KAYA, ŞAHENDER GÜLBİN AYGENCEL BIKMAZ, MELDA TÜRKOĞLU, ARZU TOPELİ İSKİT, MUHAMMET GÜVEN, MURAT SUNGUR, and NERİMAN DEFINE ALTINTAŞ

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol50/iss5/5
Value of prognostic scores in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis patients in intensive care unit: a multicenter retrospective cohort study from Turkey

Uğur ÖZDEMİR1*, Ebru ORTAC ERSOY2, Recep Civan YÜKSEL3, Erhan KAYA4, Gülbin AYGENCEL1, Melda TÜRKOGLU1, Arzu TOPELİ1, Muhammet GÜVEN3, Murat SUNGUR3, Neriman Defne ALTINTAŞ4

1Division of Intensive Care Medicine, Department of Internal Medicine, Gazi University School of Medicine, Ankara, Turkey
2Division of Intensive Care Medicine, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
3Division of Intensive Care Medicine, Department of Internal Medicine, Erciyes University School of Medicine, Kayseri, Turkey
4Division of Intensive Care Medicine, Department of Internal Medicine, Ankara University School of Medicine, Ankara, Turkey

Background/aim: There is a need for a scoring system for predicting ICU prognosis of patients with ANCA-associated vasculitis (AAV), but there are limited data on it in the literature. Therefore, we aimed to determine the scores that can estimate the prognosis of patients with AAV during intensive care follow up.

Materials and methods: All adult patients admitted to the medical ICUs of 4 reference university hospitals in Turkey due to AAV activation and/or disease/treatment complications in the last 10 years were included in this study. Demographic data, treatments before ICU, the Birmingham Vasculitis Activity Score (BVAS) score at the time of vasculitis diagnosis, and BVAS, APACHE II, SOFA, and SAPS II scores at the ICU admission, treatments, procedures, and complications during ICU stay were recorded for all AAV patients.

Results: Thirty-four patients were included in the study. The median age of the patients was 60 (42–70) years, and 64.7% were male. Twenty-five patients were diagnosed with Granulomatosis with polyangiitis, and 9 were diagnosed with Microscopic polyangiitis. The most common ICU admission causes were hemorrhage (85.3%) and sepsis/septic shock (67.6%). Twenty patients (58.8%) died in the ICU follow up. There were significant differences in APACHE II (P = 0.004) and SAPS II (P = 0.044) scores between survivors and nonsurvivors, while there were no significant differences in BVAS (during diagnosis P = 0.089 and ICU admission P = 0.539) and SOFA (P = 0.097) scores. APACHE II score was found to be an independent risk factor for ICU mortality (OR = 1.231, CI 95% = 1.011–1.498, P = 0.038) according to logistic regression analysis. An APACHE II score of greater than 20.5 predicted ICU mortality with 80% sensitivity and 70% specificity (AUC = 0.8, P = 0.004, Likelihood ratio = 2.6) according to the ROC curve analysis.

Conclusion: APACHE II score can be used for the prediction of ICU mortality in AAV patients.

Key words: Antineutrophil cytoplasmic antibody, vasculitis, prognostic scores, critical care, mortality

1. Introduction
Antineutrophil cytoplasmic antibodies (ANCA) and associated vasculitis (AAV) is a small vessel vasculitis that differs from other vasculitides with its common characteristic features. AAV is characterized by necrotizing inflammation involving predominantly small vessels and accompanied by the presence of ANCA in serum [1]. The ANCA, which have a significant role in the pathogenesis of the AAV, can be against proteinase-3 (cytoplasmic, c–ANCA) or myeloperoxidase (perinuclear, p–ANCA) [2]. AAV includes microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and drug-induced AAV [3]. During the clinical course of patients in the AAV disease group, the general condition of the patients may deteriorate rapidly, and admission to the intensive care unit (ICU) may be necessary due to life threatening complications [4]. These complications can be listed as pulmonary alveolar hemorrhage, subglottic obstruction, coronary artery syndromes, intestinal ischemia and perforation, crescentic glomerulonephritis and renal failure, intracranial hemorrhage, immunosuppression due to the drugs used, pneumonia and sepsis [5]. Due to this wide range of complications, the clinical outcome of the AAV patients can be highly variable and unpredictable.
An Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score, or Simplified Acute Physiology Score (SAPS) II can be used to determine the prognosis of patients in the ICU [6]. The activation of the AAV can be associated with more severe complications and requirements of organ support. The Birmingham Vasculitis Activity Score (BVAS), which was originally developed in 1994 (version 1) [7], can be used for the evaluation of vasculitis activation of patients. Therefore, the BVAS may be useful in assessing the prognosis of patients with AAV. The BVAS has 2 new versions, version 2 and version 3. The latest version of the BVAS (version 3) was also validated for ANCA related vasculitis [8,9]. To our knowledge, there is a limited number of studies in the literature investigating the clinical and ICU outcomes of patients with AAV [4, 10–13]. In fact, these patients constitute only a small part of the patients who are admitted to the ICU [5]. However, the management of these patients in ICUs can be quite difficult due to unexpected life threatening complications associated with acute vasculitic manifestations and immunosuppressive therapies. We less encountered this patient population in intensive care practice. For these reasons, in this multicenter, retrospective study, we planned to determine the clinical factors that can influence prognosis, the prognostic importance of the activation degree of the vasculitis (by BVAS version 3) and especially the prognostic importance of prognostic scores, which are frequently used in intensive care practice (by the APACHE II score, SOFA score, SAPS II score).

2. Materials and methods
2.1. Patient population
This retrospective multicenter study included patients with ANCA associated vasculitis (AAV) who needed medical ICU admission in 4 reference hospitals of Turkey. Three of these hospitals are located in Ankara province. These are Gazi University Hospital, Hacettepe University Hospital, and Ankara University Ibn-i Sina Hospital, respectively. The other reference hospital is Erciyes University Hospital in Kayseri province. All patients who were diagnosed with ANCA associated vasculitis before or during ICU stay, who were older than 18 years of age, and who needed to be followed up in medical ICU between January 1, 2008 and January 1, 2018 were included in this study. For AAV patients with more than one ICU admission, only those who were admitted to the ICU for the first time were included in the study. The AAV diagnosis of all patients included in this study was consistent with the criteria of the European Medicines Agency vasculitis classification [14]. This study was approved by the Local Ethics Committee of Gazi University (date: March 26, 2018 and issue: 234).

2.2. Clinical information about patients
The following data were obtained from AAV patients: demographic data, test results of ANCA (by immunofluorescence), pathological data if available, duration from diagnosis of AAV to ICU admission, the class of AAV diagnosis according to the European Medicines Agency vasculitis classification, BVAS score at the diagnosis (BVASdg), and BVAS score at the ICU admission (BVASicu), length of ICU stay, mechanical ventilation requirement, the main reasons of the ICU admission, Glasgow Coma Scale (GCS), hemodialysis and continuous renal replacement therapy requirement, AAV related organ involvements, immunosuppressive treatments and doses of the drugs used, plasmapheresis requirements, routine laboratory tests, infections, sepsis, septic shock, and related microorganisms. The following scores were also obtained from the patients 24 h after ICU admission; Acute Physiology and Chronic Health Evaluation (APACHE) II score, Sequential Organ Failure Assessment (SOFA) score, Simplified Acute Physiology Score (SAPS) II. Patients diagnosed with AAV within the last 30 days before ICU admission or during ICU stay were considered as newly diagnosed patients [10]. On the other hand, the case of patients who had more than 30 days between AAV diagnosis and ICU admission and were admitted to ICU with new vasculitis involvement was considered as a relapse.

2.3. Statistical analysis
Statistical analysis was performed using the IBM SPSS statistical software package version 22 (IBM Corp., Armonk, NY, USA). Because this study group was small, continuous variables were accepted as nonnormally distributed and were described as median and interquartile ranges. Categorical variables were presented as frequencies and percentages. Patients were divided into 2 groups as survivors and nonsurvivors. The Mann-Whitney U test was used to compare the continuous variables between the 2 independent groups. The Chi-square test was used to compare categorical variables. Among the variables that indicated statistically significant differences regarding mortality, the logistic regression analysis was performed to determine the variables that were independently related to mortality. After the determination of independent risk factors for mortality, ROC (Receiver Operating Characteristic) curve analyses were performed.

3. Results
Thirty-four patients were included in the study. The median BVAS value at the diagnosis of AAV was 23. c–ANCA was determined in 24 (70.6%) patients, and p–ANCA was determined in 12 (35.3%) patients. Twenty-five (73.5%) patients were diagnosed with GPA, and 9 (26.5%) were diagnosed with MPA. The demographic and clinical data of the study patients and their statistical differences according to mortality are presented in Table 1. Only 3 patients were
Table 1: Demographic and clinical data of AAV patients.

| Parameters                               | All patients (n = 34) | Survivors (n = 14) | Nonsurvivors (n = 20) | P value |
|------------------------------------------|-----------------------|--------------------|-----------------------|---------|
| Age (Years)*                             | 60 [42–70]           | 63 [47–70]         | 57 [40–70]           | 0.592   |
| Sex, M, n (%)                            | 22 (64.7)            | 9 (64.3)           | 13 (65)              | 0.966   |
| Smoking, n (%)                           | 10 (29.4)            | 5 (35.7)           | 5 (25)               | 0.506   |
| Chronic kidney disease, n (%)            | 14 (41.2%)           | 6 (42.9)           | 8 (40)               | 0.870   |
| AKIN stage 1/2/3, n (%)                  | 2 (14.3) / 1 (7.1) / 11 (78.6) |                    |                      |         |
| Essential hypertension, n (%)            | 11 (32.4%)           | 6 (42.9)           | 5 (25)               | 0.396   |
| Coronary artery disease, n (%)           | 6 (17.6)             | 3 (21.4)           | 3 (15)               | 0.634   |
| Heart failure, n (%)                     | 5 (14.7)             | 3 (21.4)           | 2 (10)               | 0.362   |
| Rheumatoid arthritis, n (%)              | 3 (8.8)              | 2 (14.3)           | 1 (5)                | 0.355   |
| Type 2 diabetes mellitus, n (%)          | 2 (5.9)              | 1 (7.1)            | 1 (5)                | 0.931   |
| Hypothyroidism, n (%)                    | 2 (5.9)              | -                  | 2 (10)               | 0.230   |
| SLE, n (%)                               | 1 (2.9)              | -                  | 1 (5)                | 0.403   |
| APACHE II score*                         | 23 [18–28]           | 17 [11–24]         | 25 [21–30]           | **0.004** |
| SOFA score *                             | 7 [5–10]             | 6 [4–8]            | 9 [5–10]             | 0.097   |
| BVAS*                                    | 23 [16–30]           | 21 [13–29]         | 24 [16–31]           | 0.539   |
| SAPS II*                                 | 44 [34–52]           | 40 [33–44]         | 49 [37–58]           | **0.044** |
| GCS*                                     | 14 [11–15]           | 14 [13–15]         | 13 [8–14]            | 0.164   |
| Days from diagnosis to ICUad *           | 25 [0–430]           | 14 [0–588]         | 33 [0–166]           | 0.972   |
| IMV, n (%)                               | 7 (20.6)             | 2 (14.3)           | 5 (25)               | 0.616   |
| NIMV, n (%)                              | 15 (44.1)            | 5 (35.7)           | 10 (50)              | 0.500   |
| Hemorrhage, n (%)                        | 29 (85.3)            | 10 (71.4)          | 19 (95)              | 0.966   |
| · Massive hemoptysis, n (%)              | 20 (58.8)            | 7 (50)             | 13 (65)              | 0.389   |
| · GIS bleeding, n (%)                    | 7 (20.6)             | 1 (7.1)            | 6 (30)               | 0.110   |
| · Hematuria, n (%)                       | 2 (5.9)              | 2 (14.3)           | -                    | 0.086   |
| Infection, n (%)                         | 32 (94.1)            | 13 (92.9)          | 19 (95)              | 0.797   |
| · Pneumonia, n (%)                       | 28 (82.4)            | 11 (78.6)          | 17 (85)              | 0.634   |
| · UTI, n (%)                             | 3 (8.8)              | 2 (14.3)           | 1 (5)                | 0.355   |
| · CRBSI, n (%)                           | 3 (8.8)              | 2 (14.3)           | 1 (5)                | 0.355   |
| Septic shock, n (%)                      | 23 (67.6)            | 9 (64.3)           | 14 (70)              | 0.730   |
| Intubation requirement, n (%)            | 21 (61.8)            | 6 (42.9)           | 15 (75)              | 0.061   |
| IMV, n (%)                               | 27 (79.4)            | 7 (50)             | 20 (100)             | **0.0001** |
| NIMV, n (%)                              | 20 (58.8)            | 9 (64.3)           | 11 (55)              | 0.594   |
| Tracheostomy, n (%)                      | 3 (8.8)              | -                  | 3 (15)               | 0.135   |
| New onset infection, n (%)               | 23 (67.6)            | 6 (42.9)           | 17 (85)              | **0.011** |
| · Pneumonia, n (%)                       | 22 (64.7)            | 6 (42.9)           | 16 (80)              | **0.028** |
| · UTI, n (%)                             | 4 (11.8)             | -                  | 4 (20)               | 0.079   |
| · CRBSI, n (%)                           | 2 (5.9)              | -                  | 2 (10)               | 0.230   |
| New onset sepsis, n (%)                  | 15 (44.1)            | 1 (7.1)            | 14 (70)              | **0.0001** |
| New onset septic shock, n (%)            | 14 (41)              | 3 (21.4)           | 11 (55)              | 0.054   |
| HD requirement, n (%)                    | 22 (64.7)            | 8 (57.1)           | 14 (70)              | 0.447   |
| CRRT requirement, n (%)                  | 11 (32.4)            | -                  | 11 (55)              | **0.001** |
| Length of ICU stay (day)*                | 15 [7–24]            | 13 [7–20]          | 17 [7–25]            | 0.451   |

*Data are presented as median [interquartile range], n: number; M: male; BVAS: Birmingham Vasculitis Activity Score; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; GCS: Glasgow Coma Scale; SAPS: Simplified Acute Physiology Score; CRRT: Continuous Renal Replacement Therapy; ICUad: Intensive Care Unit admission; IMV: Invasive mechanical ventilation; NIMV: Noninvasive mechanical ventilation; GIS: Gastrointestinal system; UTI: Urinary tract infection; CRBSI: Catheter-related bloodstream infection; SLE: Systemic lupus erythematosus; AKIN: acute kidney injury network; HD: hemodialysis;
diagnosed with AAV during ICU stay, but all of the others had been diagnosed with AAV before ICU admission. According to table 2, there were not differences between survivor and nonsurvivor patients in terms of disease related features, except than presences of septic shock. The respiratory failure due to hemorrhage and sepsis/septic shock were the main reason of the ICU admission (Table 2). Twenty patients (58.8%) died during ICU stay. Twelve patients died due to septic shock (60%). Four of them died due to massive hemoptysis and respiratory failure (20%). Two of them died due to hemorrhagic shock (10%). One of them died due to cardiogenic shock (5%). One of them died due to resistant pulmonary edema and respiratory failure (5%). Some laboratory results of the survivors and nonsurvivors are shown in Table 3. Statistically significant differences were found in clinical prognostic scores (APACHE II and SAPS II) between survivors and nonsurvivors. Also, immunosuppressive therapies applied before ICU admission and during ICU stay in survivors and nonsurvivors are presented in Table 4. There was no difference between survivors and nonsurvivors in terms of immunosuppressive therapies. New–onset infections and related pathogenic microorganisms in AAV patients during ICU stay are listed in Table 5. APACHE II score was found to be an independent risk factor for ICU mortality when the logistic regression analysis was performed between APACHE II, SAPS II, SOFA scores, BVAS at the diagnosis, serum ALT level and blood platelet count (Table 6). The cutoff value of the APACHE II score for prediction of ICU mortality in AAV patients was found to be 20.5 with 80% sensitivity and 70% specificity (AUC = 0.800, P = 0.004, LR = 2.6) according to Receiver Operating Characteristic (ROC) analysis (Figure).

4. Discussion
ANA associated vasculitis patients are accepted to ICUs due to the initial presentation of the vasculitis or the result of progressive primary or recurrent/refractory disease

| Parameters, n (%) | All (n = 34) | Survivors (n = 14) | Nonsurvivors (n = 20) | P value |
|-------------------|-------------|-------------------|----------------------|---------|
| c-ANCA            | 24 (70.6%)  | 10 (71.4%)        | 14 (70%)             | 0.986   |
| p-ANCA            | 12 (35.3%)  | 5 (35.7%)         | 7 (35%)              | 0.959   |
| GPA               | 25 (73.5%)  | 10 (71.4%)        | 15 (75%)             | 0.819   |
| MPA               | 9 (26.5%)   | 4 (28.6%)         | 5 (25%)              | 0.819   |
| BVAS at the diagnosis* | 23 [19–29] | 20 [12–28]        | 24 [20–31]           | 0.089   |
| Active vasculitis | 30 (88.2%)  | 12 (85.7%)        | 18 (90%)             | 0.707   |
| New-diagnosed AAV | 18 (52.9%)  | 8 (57.1%)         | 10 (50%)             | 0.686   |
| Relapsed AAV      | 12 (35.3%)  | 4 (28.6%)         | 8 (40%)              | 0.499   |
| Pulmonary-renal syndrome | 22 (64.7%) | 9 (64.3%)        | 13 (65%)             | 0.966   |
| Only pulmonary involvement | 7 (20.6%) | 2 (14.3%)     | 5 (25%)              | 0.454   |
| Cardiovascular system | 8 (23.5%) | 2 (14.3%)      | 6 (30%)              | 0.298   |
| Central nervous system | 8 (23.5%) | 2 (14.3%)   | 6 (30%)              | 0.295   |
| Gastrointestinal system | 7 (20.6%) | 1 (7.1%)     | 6 (30%)              | 0.110   |
| Eye               | 5 (14.7%)   | 3 (21.4%)         | 2 (10%)              | 0.362   |
| Skin              | 5 (14.7%)   | 1 (7.1%)          | 4 (20%)              | 0.305   |
| Upper airway      | 5 (14.7%)   | 2 (14.3%)         | 3 (15%)              | 0.955   |
| Respiratory failure due to massive hemoptysis | 14 (41.2%) | 7 (50%) | 7 (35%) | 0.478 |
| Septic shock      | 9 (26.5%)   | -                 | 9 (45%)              | **0.027** |
| Sepsis without shock and impaired consciousness | 4 (11.8%) | 3 (21.4%) | 1 (5%) | 0.436 |
| Heart failure and pulmonary edema | 3 (8.8%) | 2 (14.3%) | 1 (5%) | 0.666 |
| Gastrointestinal bleeding and shock | 2 (5.9%) | 1 (7.1%) | 1 (5%) | 0.797 |
| Kidney failure and pulmonary edema | 2 (5.9%) | 1 (7.1%) | 1 (5%) | 0.797 |

*Data are presented as median [interquartile range] n: number; AAV: Antineutrophil Cytoplasmic Antibody Associated Vasculitis; c-ANCA: Cytoplasmic Antineutrophil Cytoplasmic Antibodies; p-ANCA: Perinuclear Antineutrophil Cytoplasmic Antibodies; GPA: Granulomatosis with polyangiitis; MPA: Microscopic polyangiitis; BVAS: Birmingham Vasculitis Activity Score;
Table 3: Some laboratory data for all AAV patients including survivors and nonsurvivors.

| Parameters                  | All (n = 34) | Survivors (n = 14) | Nonsurvivors (n = 20) | P value |
|-----------------------------|-------------|--------------------|-----------------------|---------|
| Max. sAST (U/L)*            | 48 [35–282] | 38 [32–66]         | 103 [40–912]          | 0.016   |
| Max. sALT (U/L)*            | 60 [22–193] | 39 [18–63]         | 124 [48–638]          | 0.014   |
| Max. sT.Bil.(mg/dL)*        | 1.7 [1–4.2] | 1.2 [0.6–1.7]      | 3.8 [1.4–7.4]         | 0.005   |
| Max. sLactat (mmol/L)*      | 4 [2.2–9.9] | 2.1 [1.4–3.8]      | 6 [3.7–15.5]          | 0.001   |
| Max. sCRP (mg/L)*           | 151 [32–207] | 60 [20–200]       | 175 [101–233]         | 0.041   |
| Max. sPRC (ng/mL)*          | 19.5 [2.2–73] | 3 [0.2–23]       | 29 [4.8–82]           | 0.024   |
| Min. bWBC (x10^3/μL)*      | 3.4 [1.2–6.2] | 4.4 [3.3–7.6]      | 2.2 [0.6–4.1]         | 0.027   |
| Min. bPlatelet (x10^3/μL)*  | 38 [9.5–86] | 78 [67–203]        | 12.4 [5.7–31.5]       | 0.0001  |
| Min. arterial pH*           | 7.13 [7.0–7.2] | 7.2 [7.1–7.3]     | 7.07 [6.9–7.1]        | 0.0001  |

*Data are presented as median [interquartile range], s: serum; b: blood; Max: Maximum; Min: Minimum; AAV: Antineutrophil Cytoplasmic Antibody Associated Vasculitis; CRP: C-Reactive Protein; PRC: Procalcitonin; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; T.Bil: Total Bilirubin; PH: Power of Hydrogen;

Table 4: Immunosuppressive therapies in all AAV patients including survivors and nonsurvivors.

| Parameters                  | All (n = 34) | Survivors (n = 14) | Nonsurvivors (n = 20) | P value |
|-----------------------------|-------------|--------------------|-----------------------|---------|
| Before ICU admission        |             |                    |                       |         |
| Methylprednisolone, n (%)   | 26 (76.5)   | 9 (64.3)           | 17 (85)               | 0.167   |
| Cyclophosphamide, n (%)     | 20 (58.8)   | 7 [50]             | 13 (65)               | 0.389   |
| Rituximab, n (%)            | 6 (17.6)    | 3 (21.4)           | 3 (15)                | 0.634   |
| Plasmapheresis, n (%)       | 16 (47.1)   | 4 (28.6)           | 12 (60)               | 0.075   |
| Total seans*, count         | 5 [4–7]     | 5 [2–9]            | 6 [4–7]               | 0.691   |
| During ICU stay             |             |                    |                       |         |
| Methylprednisolone, n (%)   | 31 (91.2)   | 13 (92.9)          | 18 (90)               | 0.776   |
| Cyclophosphamide, n (%)     | 7 (20.6)    | 5 (35.7)           | 2 (10)                | 0.072   |
| Rituximab, n (%)            | 1 (2.9)     | -                  | 1 (5)                 | -       |
| Plasmapheresis, n (%)       | 18 (52.9)   | 8 (57.1)           | 10 (50)               | 0.686   |
| Total seans*, count         | 4 [3–5]     | 5 [3–6]            | 3 [3–5]               | 0.256   |

*Data are presented as median [interquartile range] AAV: Antineutrophil Cytoplasmic Antibody Associated Vasculitis; n: number; ICU: Intensive Care Unit

Table 5: New onset infections related microorganisms during ICU stay in all AAV patients including survivors and nonsurvivors.

| Related microorganisms       | All (n = 34) | Survivors (n = 14) | Nonsurvivors (n = 20) | P value |
|------------------------------|-------------|--------------------|-----------------------|---------|
| Acinetobacter baumannii, n (%) | 10 (29.4) | 3 (21.4)          | 7 (35)                | 0.399   |
| Escherichia coli, n (%)      | 8 (23.5)    | 2 (14.3)          | 6 (30)                | 0.288   |
| Klebsiella pneumonia, n (%)  | 4 (11.8)    | 2 (14.3)          | 2 (10)                | 0.703   |
| Enterococcus spp, n (%)      | 4 (11.8)    | -                 | 4 (20)                | 0.075   |
| Candida spp, n (%)           | 4 (11.8)    | -                 | 4 (20)                | 0.075   |
| Stenotrophomonas maltophilia, n (%) | 2 (5.9) | -                 | 2 (10)                | 0.223   |
| Pseudomonas aeruginosa, n (%) | 2 (5.9)    | 1 (7.1)           | 1 (5)                 | 0.794   |

AAV: Antineutrophil Cytoplasmic Antibody Associated Vasculitis; n: number; ICU: Intensive Care Unit
or the result of complications of immunosuppressive treatment [15,16]. In our study, most of the patients (88.2%) had an active disease of AAV at the ICU admission (newly diagnosed or relapsing disease). Also, the majority of the study patients were admitted to our ICUs with hemorrhage (85.3% – especially massive hemoptysis) and with sepsis (67.6%).

In general, it is known that the presence of an underlying rheumatologic disease [17] or vasculitic disease in ICU patients has a negative effect on their outcome. This reality is also true for AAV patients. Previous studies have found highly heterogeneous results related to ICU mortality of AAV patients. For example, Demiselle et al. reported that the mortality rate of AAV patients with acute vasculitis manifestation was 15.5% [10]. In a similar study that included the patients of small vessel vasculitis, the mortality rate was found 16% in the ICU follow up period [13]. In other studies, the ICU mortality of the AAV patients was found as 33, 39, and 60%, respectively [4,12,18]. These variable mortality rates were probably related to the heterogeneity of included patients. In our study, we found that the ICU mortality rate of AAV patients was 58.8%. It was slightly higher than the previous studies. Reasons for the higher mortality observed in our patient group might be the presence of high rate of active vasculitis, renal and pulmonary insufficiency related with active vasculitis, high requirements of mechanical ventilation, and renal replacement therapy and presence of high rate of infection and sepsis at the ICU admission or during the ICU stay. Also, our departments are referral centers for patients with vasculitis. Patients with worse conditions or those who do not respond adequately to standard therapy, in particular, are referred to our centers. This situation may have led to higher mortality rates in our study. In our opinion and experience, this result is important because this group of diseases is associated with severe complications that may lead to fatal outcomes.

As for the role of prognostic scores (APACHE II, SOFA, SAPS II, etc.) in predicting the outcome of patients with AAV admitted to the ICU, our results confirmed the findings of previous studies. Both APACHE II and SAPS II scores were significantly higher in nonsurvivors than in survivors. This finding seems to be consistent with the literature. In the study of Frausova et al. [4], there was a statistically significant difference in the APACHE II score for ICU mortality. Also, in the studies of Demiselle et al. [10] and Kimmoun et al. [13], there were statistically

Table 6: Logistic regression analysis for the determination of independent risk factors for ICU mortality in AAV patients.

| Parameters              | P value | Wald    | Exp (B) | CI 95% (Confidence Interval) |
|-------------------------|---------|---------|---------|-----------------------------|
| APACHE II score         | 0.038   | 4.295   | 1.231   | 1.011–1.498                 |
| SAPS II score           | 0.895   | 0.017   | 0.993   | 0.893–1.104                 |
| SOFA score              | 0.949   | 0.004   | 0.988   | 0.681–1.434                 |
| BVAS at the diagnosis   | 0.473   | 0.514   | 1.034   | 0.944–1.132                 |
| Serum ALT level         | 0.600   | 0.275   | 1.005   | 0.988–1.022                 |
| Serum Platelet count    | 0.473   | 0.127   | 1.034   | 0.944–1.132                 |

AAV: Antineutrophil Cytoplasmic Antibody Associated Vasculitis; APACHE: Acute Physiology and Chronic Health Evaluation; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment; BVAS: Birmingham Vasculitis Activity Score; ICUad: ALT: Alanine aminotransferase
significant differences for SAPS II scores according to ICU mortality. In the study of Cruz et al. [12], there were statistically significant differences in APACHE II and SAPS II scores according to ICU mortality. But SAPS II and APACHE II scores, which are nonspecific ICU severity scores assessed at admission, were generally found to be predictive of ICU mortality in all types or all groups of ICU patients. Nevertheless, we found that if the APACHE II score was equal or higher than 20.5 at the time of ICU admission, the chance of survival decreased significantly in our AAV patients. Burkhardt et al. reported similar results in patients with Wegener's granulomatosis [19].

Some studies have shown a relationship between vasculitic activity and long-term and short-term (such as in ICU mortality) prognosis [20, 21]. BVAS score has been used most frequently in these studies. BVAS has become the current standard assessment tool for scoring activity in AAV. But in our study, we did not find any correlation between vasculitis disease activity (assessed by BVAS) and ICU mortality. BVAS (neither BVAS on the first ICU day nor BVAS at vasculitis diagnosis) was not associated with ICU mortality in our study. This finding is supported by other studies investigating ICU mortality of AAV patients [4,10–13]. It is known, however, that BVAS was designed to assess vasculitic patients prospectively, and the retrospective analysis might have underestimated the score.

Apart from these prognostic scoring systems, in the literature, some factors have been stated to have prognostic importance in the short-term mortality of the AAV patients. These factors can be listed as the presence of infections, requirements of vasopressors, mechanical ventilation and blood transfusion, usage of cyclophosphamide, and renal failure [2,10]. In our study, new onset ICU infections, shock and vasopressor requirements, thrombocytopenia and platelet transfusion requirements, and liver dysfunction can be listed as factors that were significantly related to ICU mortality of AAV patients in univariate analysis.

Several limitations must be considered when interpreting the results of this study, which include its retrospective nature and small study size. The retrospective analysis of the data might have influenced the results. Furthermore, although our departments serve as referral centers, the number of patients in our study is relatively small due to the low incidence and prevalence of the disease in general. Because this study covers a period of 10 years, the difference in treatment approach and technology over the years may have affected patient outcomes. As this is a multicenter study, there may be differences between the treatment approaches of the centers. Even so, our study is the first multicenter study from Turkey to highlight the clinical predictors of ICU mortality in patients with ANCA associated vasculitis.

In conclusion, this study is the first multicenter study from Turkey, which included patients who needed ICU admission for diagnosis and treatment of AAV activation or complications. The study tried to reveal factors affecting ICU mortality in patients with ANCA associated vasculitis. APACHE II score was found to be valuable for the prediction of ICU mortality in this patient group.

Acknowledgement
No financial support or grant was received for this study. The authors declare that they have no conflicts of interest.

Informed Consent
This study was approved by the Local Ethics Committee of Gazi University (date: March 26, 2018 and issue: 234).

References
1. Nakazawa D, Masuda S, Tomaru U, Ishizu A. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nature Reviews Rheumatology 2019; 15(2): 123. doi: 10.1038/s41584-019-0168-z
2. Holguin F, Ramadan B, Gal AA, Roman J. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitides. American Journal of the Medical Sciences 2008; 336(4): 321-326. doi: 10.1097/M AJ.0b013e318168056a
3. Jennette JC, Falk RJ, Bacon PA, Basu N, Gid MC et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism 2013; 65(1): 1-11. doi: 10.1002/art.37715
4. Frausova D, Brejnikova M, Hruskova Z, Rihova Z, Tesar V. Outcome of thirty patients with ANCA-associated renal vasculitis admitted to the intensive care unit. Renal Failure 2008; 30(9): 890-895. doi: 10.1080/08860220802353892
5. Janssen NM, Kardan DR, Guntupalli KK. Rheumatologic diseases in the intensive care unit: epidemiology, clinical approach, management, and outcome. Critical Care Clinics 2002; 18(4): 729-748. Review doi: 10.1016/s0749-0704(02)00025-8
6. Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Critical Care (London, England) 2010; 14(2): 207. doi: 10.1186/cc8204
7. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM: Monthly Journal of the Association of Physicians 1994; 87(11): 671-678.
8. Mukhtyar C, Lee R, Brown D, Carruthers D, Dagsuupta B et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Annals of the Rheumatic Diseases 2009; 68(12): 1827-1832. doi: 10.1136/ard.2008.101279

9. Suppiah R, Mukhtyar C, Flossmann O, Alberici F, Baslund B et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford, England) 2011; 50(5): 899-905. doi: 10.1093/rheumatology/keq400

10. Demiselle J, Auchabie J, Beloncle F, Gatault P, Grangé S et al. Patients with ANCA-associated vasculitis admitted to the intensive care unit with acute vasculitis manifestations: a retrospective and comparative multicentric study. Annals of Intensive Care 2017; 7(1): 39. doi: 10.1186/s13613-017-0262-9

11. Khan SA, Subla MR, Behl D, Specks U, Afessa B. Outcome of patients with small-vessel vasculitis admitted to a medical ICU. Chest 2007; 131(4): 972-976.

12. Cruz BA, Ramanoeina J, Mahr A, Cohen P, Mouthon L et al. Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology (Oxford, England) 2003; 42(10): 1183-1188. doi: 10.1093/rheumatology/keg322

13. Kimmoun A, Baux E, Das V, Terzi N, Talec P et al. Outcomes of patients admitted to intensive care units for acute manifestation of small-vessel vasculitis: a multicenter, retrospective study. Critical Care (London, England) 2016; 26; 20:27. doi: 10.1186/s13054-016-1189-5

14. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Annals of the Rheumatic Diseases 2007; 66(2): 222-227. doi: 10.1136/ard.2006.054593

15. Mun CH, Yoo J, Jung SM, Song JJ, Park YB et al. The initial predictors of death in 153 patients with ANCA-associated vasculitis in a single Korean centre. Clinical and Experimental Rheumatology 2018; 111(2): 65-72.

16. Pu L, Li GS, Zou YR, Zhang P, Wang L. Clinical Predictors of Outcome in Patients with Antineutrophil Cytoplasmic Autoantibody-related Renal vasculitis: Experiences from a Single-center. Chinese Medical Journal 2017; 130(8): 899-905. doi: 10.4103/0366-6999.204099

17. Ozbalkan Z, Topeli A, Kiraz S, Ozturk MA, Ertenli I et al. The contribution of underlying systemic rheumatic diseases to the mortality in patients admitted for intensive care: a matched cohort study. Clinical and Experimental Rheumatology 2004; 22(2): 223-226.

18. Włudarczyk A, Polok K, Górska J, Halek A, Biedroń G et al. Patients with small-vessel vasculitides have the highest mortality among systemic autoimmune diseases patients treated in intensive care unit: A retrospective study with 5–year follow up. Journal of Critical Care 2018; 48: 166-171. doi: 10.1016/j.jcrc.2018.08.037

19. Burkhardt O, Köhnlein T, Wrenger E, Lux A, Neumann KH et al. Predicting outcome and survival in patients with Wegener's granulomatosis treated on the intensive care unit. Scandinavian Journal of Rheumatology 2007; 36(2): 119-24. doi: 10.1080/03009740600958611

20. Biscetti F, Carbonella A, Parisi F, Bosello SL, Schiavon F et al. The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). Medicine (Baltimore) 2016; 95(48): e5506. doi: 10.1097/MD.0000000000005506

21. Solans-Laqué R, Rodriguez-Carballeira M, Ríos-Blanco JJ, Fraile G, Sáez-Comet L et al. Spanish Registry of systemic vasculitis (REVAS); Autoimmune Systemic Diseases Study Group (GEAS); Spanish Society of Internal Medicine (SEMI). Comparison of the Birmingham vasculitis activity score and the five factors score to assess survival in ANCA-associated vasculitis. Arthritis Care & Research (Hoboken) 2019. doi: 10.1002/acr.23912